Roche and Toyama Chemical Co. have entered into a licensing agreement for the research, development and commercialization of Toyama’s oral rheumatoid arthritis agent T-5224. By inhibiting a specific inflammatory process, T-5224 has the potential to block signs and symptoms of rheumatoid arthritis and the progressive destruction of joint and bone. The compound is currently in Phase I. Under the terms of the agreement, Roche has been granted exclusive rights to research, develop, and m...